Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
IKT Inhibikase Therapeutics
0.600
-0.005-0.83%
Post Mkt Price
0.6000.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
ROIC
4.54% -54.420% -48.63% -49.096% 57.39% -79.824% 35.31% -60.902%
ROE
4.32% -55.102% -44.93% -49.097% 73.03% -79.863% 42.97% -61.353%
ROA
-9.23% -50.548% -56.58% -45.172% 19.42% -66.806% -34.40% -51.652%
Efficiency Ratios
Profitability Ratios TTM
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- 0.923% -- -- -- -- -- --
Total Assets to Common Equity
6.99% 113.705% 10.16% 115.220% -23.60% 112.879% -26.83% 110.554%
Debt to Asset Ratio
158.05% 1.488% -- -- -- -- -80.13% 0.648%
Current Ratio
-48.58% 8.7104 -70.62% 7.5606 164.94% 8.7643 234.59% 10.4749
Quick Ratio
-50.35% 8.2627 -71.06% 7.1752 202.08% 8.3693 241.04% 10.0779
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- -- 0.000%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. It operates through RAMP? Drug Innovation Engine technology. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.
CEO: Dr. Milton H. Werner, PhD
Market: NASDAQ
Listing Date: 12/23/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist